All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study
Publication
, Conference
Jacobson, IM; Marcellin, P; Mangia, A; Kwo, PY; Foster, G; Buti, M; Brau, N; Muir, AJ; Yang, JC; Mo, H; Ding, X; Pang, P; Symonds, WT ...
Published in: GASTROENTEROLOGY
May 1, 2014
Duke Scholars
Published In
GASTROENTEROLOGY
EISSN
1528-0012
ISSN
0016-5085
Publication Date
May 1, 2014
Volume
146
Issue
5
Start / End Page
S903 / S903
Location
Chicago, IL
Publisher
W B SAUNDERS CO-ELSEVIER INC
Conference Name
55th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW)
Related Subject Headings
- Gastroenterology & Hepatology
- 3210 Nutrition and dietetics
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1109 Neurosciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Jacobson, I. M., Marcellin, P., Mangia, A., Kwo, P. Y., Foster, G., Buti, M., … Afdhal, N. H. (2014). All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study. In GASTROENTEROLOGY (Vol. 146, pp. S903–S903). Chicago, IL: W B SAUNDERS CO-ELSEVIER INC.
Jacobson, Ira M., Patrick Marcellin, Alessandra Mangia, Paul Y. Kwo, Graham Foster, Maria Buti, Norbert Brau, et al. “All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study.” In GASTROENTEROLOGY, 146:S903–S903. W B SAUNDERS CO-ELSEVIER INC, 2014.
Jacobson IM, Marcellin P, Mangia A, Kwo PY, Foster G, Buti M, et al. All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study. In: GASTROENTEROLOGY. W B SAUNDERS CO-ELSEVIER INC; 2014. p. S903–S903.
Jacobson, Ira M., et al. “All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study.” GASTROENTEROLOGY, vol. 146, no. 5, W B SAUNDERS CO-ELSEVIER INC, 2014, pp. S903–S903.
Jacobson IM, Marcellin P, Mangia A, Kwo PY, Foster G, Buti M, Brau N, Muir AJ, Yang JC, Mo H, Ding X, Pang P, Symonds WT, McHutchison JG, Zeuzem S, Afdhal NH. All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study. GASTROENTEROLOGY. W B SAUNDERS CO-ELSEVIER INC; 2014. p. S903–S903.
Published In
GASTROENTEROLOGY
EISSN
1528-0012
ISSN
0016-5085
Publication Date
May 1, 2014
Volume
146
Issue
5
Start / End Page
S903 / S903
Location
Chicago, IL
Publisher
W B SAUNDERS CO-ELSEVIER INC
Conference Name
55th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW)
Related Subject Headings
- Gastroenterology & Hepatology
- 3210 Nutrition and dietetics
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1109 Neurosciences
- 1103 Clinical Sciences